ADMA - ADMA Biologics Inc Stock Price, Fair Value and News

$19.70+0.45 (+2.34%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

ADMA Price Action

Last 7 days

2.9%

Last 30 days

28.2%

Last 90 days

16.5%

Trailing 12 Months

-1.1%

ADMA RSI Chart

ADMA Valuation

Market Cap

4.7B

Price/Earnings (Trailing)

22.39

Price/Sales (Trailing)

9.6

EV/EBITDA

28.7

Price/Free Cashflow

115.13

ADMA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ADMA Fundamentals

ADMA Revenue

Revenue (TTM)

488.6M

Rev. Growth (Yr)

12%

Rev. Growth (Qtr)

10.03%

ADMA Earnings

Earnings (TTM)

209.4M

Earnings Growth (Yr)

1.45%

Earnings Growth (Qtr)

6.46%

ADMA Profitability

Operating Margin

54.71%

EBT Margin

31.88%

Return on Equity

48.57%

Return on Assets

36.83%

Free Cashflow Yield

0.87%

ADMA Investor Care

Shares Dilution (1Y)

0.68%

Diluted EPS (TTM)

0.86

ADMA Alerts

1 major insider sales recently.

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	459.4M	474.2M	488.6M	0
2024	283.2M	330.2M	382.8M	426.5M
2023	181.9M	208.1M	234.3M	258.2M
2022	94.0M	110.1M	130.5M	154.1M
2021	48.1M	58.1M	68.5M	80.9M
2020	36.0M	37.2M	40.3M	42.2M
2019	16.5M	18.4M	21.4M	29.3M
2018	24.2M	25.4M	24.9M	17.0M
2017	11.2M	12.3M	14.1M	22.8M
2016	7.8M	8.8M	9.8M	10.7M
2015	5.9M	5.7M	6.2M	7.2M
2014	3.8M	4.6M	4.9M	5.9M
2013	1.9M	2.4M	3.2M	3.1M
2012	1.7M	1.5M	1.3M	1.1M
2011	0	0	0	1.9M
2010	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

About ADMA Biologics Inc

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

CEO	Mr. Adam S. Grossman
WEBSITE	admabiologics.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	617

ADMA Biologics Inc Frequently Asked Questions

What is the ticker symbol for ADMA Biologics Inc? What does ADMA stand for in stocks?

ADMA is the stock ticker symbol of ADMA Biologics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ADMA Biologics Inc (ADMA)?

As of Wed Dec 03 2025, market cap of ADMA Biologics Inc is 4.69 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ADMA stock?

You can check ADMA's fair value in chart for subscribers.

Is ADMA Biologics Inc a good stock to buy?

The fair value guage provides a quick view whether ADMA is over valued or under valued. Whether ADMA Biologics Inc is cheap or expensive depends on the assumptions which impact ADMA Biologics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ADMA.

What is ADMA Biologics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, ADMA's PE ratio (Price to Earnings) is 22.39 and Price to Sales (PS) ratio is 9.6. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ADMA PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on ADMA Biologics Inc's stock?

In the past 10 years, ADMA Biologics Inc has provided 0.08 (multiply by 100 for percentage) rate of return.